Agoracom Blog Home

Archive for the ‘Tetra Bio-Pharma Inc.’ Category

#Cannabis and #CBD Markets are Set to Increase in Value $N.ca $NXTTF $TBP.ca $MCOA

Posted by AGORACOM-JC at 3:59 PM on Tuesday, May 29th, 2018
  • U.S. medical cannabis market is projected to reach $19.48 billion by 2024
  • Projected growth is driven by the increasing acceptance of medical advantages associated with cannabis, particularly for patients dealing with cancer, diabetes and chronic pain

NEW YORK, May 29, 2018 — According to a report by Hexa Research, the U.S. medical cannabis market is projected to reach $19.48 billion by 2024. The projected growth is driven by the increasing acceptance of medical advantages associated with cannabis, particularly for patients dealing with cancer, diabetes and chronic pain. Symptoms and conditions that may be treated with cannabis products include cancer, HIV, AIDS, Alzheimer’s disease, and multiple sclerosis. Chronic pain accounted for 46 percent of the U.S. cannabis medical market share in 2016. According to the research, the solid cannabis edibles segment in 2016, within the U.S. market generated $2.47 billion in revenue and is expected to continue to dominate the cannabis industry to 2024. Chineseinvestors.com, Inc. (OTC: CIIX), Kush Bottles, Inc. (OTC: KSHB), General Cannabis Corporation (OTC: CANN), Isodiol International Inc. (OTC: ISOLF), PotNetwork Holdings, Inc. (OTC: POTN)

A major portion of the legal cannabis industry Cannabidiol products. Cannabidiol, or CBD, is one of at least 113 active cannabinoids identified in cannabis. The CBD market is growing rapidly in recent years due to CBD’s medical benefits. Sean Murphy, the Founder and Publisher of Hemp Business Journal, said: “Hemp Business Journal estimates the total retail value of all hemp products sold in the U.S. to be at least $688 million for 2016. We estimate the hemp industry will grow to $1.8 billion in sales by 2020, led by hemp food, body care, and CBD-based products. The data demonstrates the hemp industry is growing quickly at 22% five year CAGR and being led by food and body care products, with Hemp CBD products showing a 53% AGR.”

Source: https://www.prnewswire.com/news-releases/cannabis-and-cbd-markets-are-set-to-increase-in-value-683935941.html

Tetra Bio-Pharma $TBP.ca Signs Landmark Commercialization Term Sheet for its Lead Pharmaceutical Product, PPP001, in Israel #MMJ #Marijuana $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:14 AM on Tuesday, April 24th, 2018

Logo tetrabiopharma rgb web

  • Company has signed a first binding term sheet for the marketing and distribution of PPP001 in Israel with Kamada Ltd
  • Signing of a Definitive Distribution Agreement is expected to follow shortly
  • PPP001 is being developed to be the first smokable cannabis product for advanced cancer pain available under prescription

OTTAWA, ONTARIO–(April 24, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP) (OTCQB:TBPMF), announced today that the Company has signed a first binding term sheet for the marketing and distribution of PPP001 in Israel with Kamada Ltd., a leading pharmaceutical company. The signing of a Definitive Distribution Agreement is expected to follow shortly. PPP001 is being developed to be the first smokable cannabis product for advanced cancer pain available under prescription.

This first international market commercialization agreement represents a significant milestone and a validation of Tetra Bio-Pharma’s business model with a leading Israel-based pharmaceutical company. Israel, like Canada, is considered one of the world leaders in the production and development of cannabinoid-based products. Kamada is a company with two FDA-approved products and an Israeli-based distribution segment that has demonstrated continued growth. Tetra Bio-Pharma intends to work closely with Kamada as PPP001 advances towards regulatory approval and commercial launch in Israel.

Under the terms of the anticipated final agreement, Kamada will be responsible for registering the product, as well as all marketing and distribution, in Israel. Tetra will be eligible to receive certain milestone payments and an undisclosed percentage of the sales of PPP001 generated by Kamada in Israel.

About PPP001 

On April 4, 2018, Tetra Bio-Pharma officially started the Phase 3 trial for PPP001 indicated for terminal stage cancer patients with a goal to improving the quality of life of these patients as well as minimizing their pain. PPP001 is being developed to be the first smokable cannabis product for advanced cancer pain available under prescription.

About Tetra Bio-Pharma: Tetra Bio-Pharma (TSX VENTURE:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products. Tetra Bio-Pharma is currently developing a pipeline of five cannabinoid-based products using different delivery systems such as smokable pellets, oral tablets, eye drops and topical ointments. More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Robert (Bob) Béchard
Vice President Finance and Business Development
[email protected]
M: +1 514 817-2514

For media information, please contact:
Daniel Granger
[email protected]
ACJ Communication
O: +1 514 840 7990
M: +1 514 232 1556

The medical #marijuana industry is about to get much bigger, CannTrust CEO says $N.ca $NXTTF $TBP.ca $MCOA $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 12:11 PM on Friday, April 20th, 2018
  • The ramp up in Canada’s cannabis sector is ongoing
  • Industry estimates of sales eventually adding up to between $5 and $8 billion a year
  • By comparison, Canada produces a little under $3 billion of beer a year and about $1 billion in tobacco products.

April 19, 2018 By Jayson MacLean

Eric Paul

While all eyes are on the launch date for recreational cannabis in Canada —said to come in either late summer or early fall— the medical side of the equation should be getting the attention, as well, because it’s about to get much bigger, says Eric Paul, CEO of licensed producer CannTrust Holdings (TSX:TRST).

The ramp up in Canada’s cannabis sector is ongoing, with industry estimates of sales eventually adding up to between $5 and $8 billion a year. That’s substantial, since by comparison, Canada produces a little under $3 billion of beer a year and about $1 billion in tobacco products.

But while the rec market is getting all the focus, the medical marijuana industry both at home and abroad should be getting its props, since it’s growing by leaps and bounds.

“We’ve been astounded by the growth of the medical marijuana industry in Canada,” Eric Paul, CEO of CannTrust Holdings, tells BNN.

“Roughly ten or 12 per cent of the 80,000 doctors across Canada who could prescribe are prescribing [cannabis], and I would say we’re gaining on that for a number of reasons,” says Paul. “The first being the opiate crisis where doctors are looking for cannabis as a potential first-line therapy for pain management. The second thing is that there is more research coming out; we’re about to announce a couple of major research projects in Canada and one is a major pain management study. As these research projects produce their end result, more doctors are looking at cannabis as an alternate therapy for chronically ill people.”

Statistics Canada has reported that between April and December of last year, the number of clients registered under its Access to Cannabis for Medical Purposes Regulations (ACMPR) has gone from 174,503 to 269,502.

Paul says that CannTrust itself has a 40,000-strong patient base and is looking to jump to 100,000 in 12 months time.

“We’ve had a major expansion in Niagara: a 430,000 sq. ft. state of the art greenhouse which is up and running,” says Paul. “We believe that with that capacity and with the nature of that facility, we’ll be able to supply our current customer demand in the medical market and have sufficient capacity to handle the first generation of recreational demand.”

But aside from Canada’s own growing medical market, the international market is poised to take off in countries like Germany and Australia, and many of the top licensed producers in Canada are now lining up deals outside of Canada.

In March, CannTrust announced that it has entered into a joint venture agreement with a Danish company to grow and sell medical cannabis.

“The industry is globalizing much faster than any of us expected,” says Paul.

“Various countries are going into medical legislation and Denmark is one of those countries that have announced that we’re fully licensed there, we’ll be building a facility there,” he said. “In that country, the government has decided to fund the cost of it for the consumer, via prescription, and they’re willing to fund 100 per cent for people with palliative or end-of-life care and 50 per cent for chronic illness. That will allow those industries to quickly garner market share. Germany is a similar kind of situation and also Australia.”

Source: https://www.cantechletter.com/2018/04/the-medical-marijuana-industry-is-about-to-get-much-bigger-canntrust-ceo-says/

Tetra Bio-Pharma $TBP.ca Clinical Study on Cannabis Oil Capsules for Patients Suffering from Chronic Pain should be completed by Fall 2018 $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:05 AM on Thursday, April 12th, 2018

Logo tetrabiopharma rgb web

  • Provides a status report on its encapsulated cannabis oils (PPP005) clinical trials and that these cannabis products are ready to commercialize in the retail market post-legalization
  • authorization from the Office of Controlled Substances marks the initiation of the treatment phase of the Phase 2 clinical trial that will be used to support Product License Applications post legalization
  • Tetra is performing this clinical study to obtain safety and efficacy data to support modern claims for the use of encapsulated cannabis oils in the treatment of chronic pain

OTTAWA, ONTARIO–(April 12, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP) (OTCQB:TBPMF), provides a status report on its encapsulated cannabis oils (PPP005) clinical trials and that these cannabis products are ready to commercialize in the retail market post-legalization.

Natural health products and OTC medications

The authorization from the Office of Controlled Substances marks the initiation of the treatment phase of the Phase 2 clinical trial that will be used to support Product License Applications post legalization. Tetra is performing this clinical study to obtain safety and efficacy data to support modern claims for the use of encapsulated cannabis oils in the treatment of chronic pain. Tetra’s program is designed to build a leading position in the development and commercialization of cannabis-based natural health products. Tetra’s products are being developed to be compliant with standards expected for pharmaceutical products which will be supported by scientific and clinical evidence.

PPP005 Phase 1 Clinical trial

Phase 1 clinical trial to assess safety, tolerability and pharmacokinetics of single and multiple dose of encapsulated cannabis oil (10 mg THC with 10 mg CBD) will be completed soon. “This study will provide cardiovascular safety data to ensure that the oil formulations can be safely used by consumers. The pharmacokinetic data will provide the data required to define the frequency of dosing needed to avoid inappropriate use that could lead to accumulation of cannabinoids in the body,” said Dr. Guy Chamberland, M.Sc., Ph.D., interim CEO and Chief Scientific Officer.

PPP005 Phase 2 Clinical trial

On March 22, 2018, Santé Cannabis, the Montreal-based clinic that is conducting the Phase 2 clinical trial for Tetra, received authorization from the Office of Controlled Substances to use the cannabis oil capsules of PPP005 (controlled substance).

This authorization allowed the Principal Investigator of the trial, Dr. Antonio Vigano, to proceed with the clinical trial of PPP005 in chronic pain patients. This exemption allows Santé Cannabis to prescribe the blinded study medication and for Aphria Inc to ship blinded products to patient’s home under the jurisdiction of the ACMPR. The screening and enrolment is proceeding faster than expected and will allow Tetra to meet its corporate objectives.

“We are performing this Phase 2 clinical trial to obtain safety and efficacy data to help drive the sales of encapsulated cannabis oil products for the treatment of chronic pain,” added Dr. Guy Chamberland. “We expect chronic pain patients to use cannabis oils, but many of these patients will also be taking opioids or other prescription medications. The capability of different doses and ratios of medical cannabis oil to change the amount and type of concomitant medications, such as opioids, used for pain, and the need for rescue pain medication to control chronic non-cancer and cancer pain is evaluated. The use of measures that quantify different pain drug regimens used by the patients will help us understand the potential of cannabis oils to be used for opioid sparing. The trial should be completed by fall 2018.”

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products. Tetra Bio-Pharma is currently developing a pipeline of five cannabinoid-based products using different delivery systems such as smokable pellets, oral tablets, eye drops and topical ointments.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
[email protected]
(514) 360-8040 Ext. 210

For media information, please contact:
Daniel Granger
[email protected]
ACJ Communication
O: 1 514 840 7990
M: 1 514 232 1556

Medical #marijuana making a big difference in the lives of sick children and their families $TBP.ca $N.ca $NXTTF $MCOA $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 11:06 AM on Wednesday, April 11th, 2018

“That makes all of the work we did worthwhile.”

ByCharlie Deitch @CharlieDee71

CP photo by Renee Rosensteel, Hannah Pallas laughs with her mother, Heather Shuker

Stretched out in his recliner, Ryan Briggs is having a great nap. Laying there in his Bob Marley T-shirt, you can hear him gently snoring. Although his slumber is intermittently interrupted by a slight seizure, this is starting out as a good day.

At just 18, Briggs has already had a pretty rough life. When he was born, doctor error caused the child to go more than 20 minutes without oxygen. Briggs lived, but is nonverbal and unable to care for himself. Worse than that, though, were the seizures. He experienced close to 500 of them every day — some smaller, others larger and more violent. He received all kinds of treatments and medication, but few of them helped; some made things even worse. But his mother, Diana Briggs, was determined to keep looking for that one thing that would help.

“We went everywhere for treatment,” she says. “We did one called the starvation diet, we did hyperbaric treatments and even went out of the country for stem-cell treatments. But nothing seemed to help. The seizures would get so bad, and they were frequent. We tracked every one of them. In fact, that’s how my youngest daughter learned to count, by counting her brother’s seizures.”

In 2014, Briggs saw a video that changed her life. It provided the same epiphany that parents across the state would have as the video was shared widely. The video showed that oil extracted from marijuana worked to stop the seizures of a 5-year-old Colorado girl named Charlotte Figi. Subsequently, a large group of parents across the state banded together to fight to bring medical marijuana to Pennsylvania. It was an uphill fight, but on April 17, 2016, Gov. Tom Wolf signed the legislation into law, and earlier this year, Pennsylvanians could begin legally purchasing medical cannabis.

There is no question that without the parents of sick children stepping forward to fight this battle, the law would never have been approved. But, as Briggs says, “It’s easy to say no to an adult, but it’s pretty hard to do that to a sick kid who’s suffering.”

click to enlarge

  • Ryan Briggs and his family pose for a photo with Gov. Tom Wolf the day he signed the medical-marijuana bill into law.

When the World Medical Cannabis Conference & Expo opens in Pittsburgh later this week, there will be many panels on “children and cannabis.” With that in mind, City Paper checked in on some families who have spent the past four years fighting for legalization and see how their lives have changed. Aside from Briggs, we also talked to Heather Shuker, an outspoken advocate for the product and the mother of Hannah Pallas, a 15-year-old who has dealt with intractable epilepsy her entire life.

“A few years ago, Hannah was confined to a chair, she never smiled, she couldn’t lift her extremities, she was non-verbal,” Shuker says, as a walking, squealing Hannah moves about their apartment from room to room. “Look at her now. She has found her voice, and she has found her smile again. It’s an amazing transformation.”

An obvious positive of medical-marijuana dispensaries opening up across the state is having available product close by. But for many parents, this won’t be the first time they’ve purchased these medications. Last year, the state enacted a safe-harbor provision that made it legal for anyone who is qualified to receive the drug to have it in their possession. Many parents began going out of state for the product, and since it was still illegal in several states, transporting it over state lines was a felony. For other parents, though, having safe-harbor protections still wasn’t their first foray into buying medical marijuana.

“I haven’t talked about this much before, obviously, but we’ve been experimenting with Hannah’s medication for a few years now,” Shuker says. Sometime between 2014 and 2015, Shuker began going out of state to get medical-marijuana products. She always traveled by plane and brought the oils back with her on the plane, a nerve-wracking experience. “I knew it was a risk, and I knew it would be bad if I got caught, because someone could try to take Hannah away,” she says. “But my daughter was sick, with zero quality of life. I had to help her, so at the end of the day, it wasn’t really a choice at all.”

Briggs had the same feeling that Shuker did. She would fly to Colorado to get medication and bring it back with her. Once, because of some change she forgot to take out of her pocket, she was pulled aside and given a complete search, including having her bags searched. They didn’t find the oil, but it made for a tense moment.

Because of the cost of going to Denver and the risk, she decided to find a local contact. While she won’t give many details about the person or the transactions, she says the dealer became part of the family.

“That first Christmas, I baked him some cookies,” Briggs says. “I didn’t think it was strange at the time. I’m a mom — that’s what we do for family and friends, we bake cookies.”

The other thing moms do is help others in need.

Source: https://www.pghcitypaper.com/pittsburgh/medical-marijuana-making-a-big-difference-in-the-lives-of-sick-children-and-their-families/Content?oid=7667617

Tetra Bio-Pharma $TBP.ca Initiates Enrollment of Patients in Phase 3 PPP001 Smokable Cannabis Pellet Study $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:58 AM on Wednesday, April 4th, 2018

Logo tetrabiopharma rgb web

  • Announced the initiation of screening and enrollment activities in the Phase 3 study of its PPP001 smokable cannabis pellet for advanced cancer patients with uncontrolled pain
  • Tetra authorized the initiation of the patient enrollment activities at its main clinical site, Santé Cannabis, a private medical cannabis clinic in Montreal which is in compliance with Health Canada Division 5 regulations and the International Conference on Harmonization (ICH) Good Clinical Practices (GCP) (E6) R2

1st Canadian Cannabis Smokable Pellet Study 1st Step Towards Pharmaceutical Distribution of Cannabis

OTTAWA, ONTARIO–(April 4, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP) (OTCQB:TBPMF), today announced the initiation of screening and enrolment activities in the Phase 3 study of its PPP001 smokable cannabis pellet for advanced cancer patients with uncontrolled pain.

Tetra authorized the initiation of the patient enrollment activities at its main clinical site, Santé Cannabis, a private medical cannabis clinic in Montreal which is in compliance with Health Canada Division 5 regulations and the International Conference on Harmonization (ICH) Good Clinical Practices (GCP) (E6) R2.

PPP001 aims to be the first smokable cannabis for advanced cancer pain available under prescription. It is a dried cannabis pellet designed to be smoked in an inhalation device specifically developed for this product. PPP001 is a unique blend of 3 strains of standardized dried cannabis, creating a drug substance with 9.5% THC and 2.5% CBD.

“This is a significant milestone in the lead product of our strong pipeline of cannabinoid-based drugs targeting patients with advanced pain,” said Guy Chamberland, Tetra’s CEO and CSO. “The launch of the Phase 3 clinical trial will be used to support the marketing application of PPP001 smokable pellet that is followed by four other cannabinoid-based products that we are developing using different delivery systems such as oral tablets, eye drops, topical ointments and oral capsules of cannabis oil.”

On February 28th, 2018, Santé Cannabis received authorization from the Office of Controlled Substances to use PPP001 (controlled substance) for the Phase 3 clinical trial. This authorization granted the Principal Investigator of the Phase 3 trial, Dr. Antonio Vigano, exemption from the application of several provisions of the Controlled Drugs and Substances Act and the Narcotic Control Regulations thereby allowing the investigator to proceed with the clinical study of PPP001 in advanced cancer patients. In addition, the exemption allows Santé Cannabis to store and dispense the study medication directly to the patients, a process not permitted by Licensed Producers under the ACMPR.

“We are performing the first large study of the safety and efficacy of a dried cannabis smoked drug in advanced cancer patients,” added Guy Chamberland. “Over the next month Tetra will expand the trial by working with other clinics across Canada. Most importantly, we believe this multisite study has the potential to change the current vision of the use of smoked cannabis as an effective palliative care therapy of patients with advanced cancer.”

About PPP001:

PPP001 aims to be the first smokable marihuana for advanced cancer pain under prescription. It is a dried cannabis pellet designed to be smoked in an inhalation device specifically developed for this product. PPP001 is a unique blend of 3 strains of standardized dried cannabis, creating a drug substance with 9.5% THC and 2.5% CBD.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princeps product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(438) 899-7575

For media information, please contact:
Daniel Granger
[email protected]
ACJ Communication
O: 1 514 840 7990
M: 1 514 232 1556

For investors information, please contact:
[email protected]
(438) 504-5784

Tetra Bio-Pharma $TBP.ca Names Guy Chamberland as Interim CEO $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 2:09 PM on Tuesday, April 3rd, 2018

Logo tetrabiopharma rgb web

  • Announced the appointment of Guy Chamberland, M.Sc., Ph.D., an accomplished drug developer, as interim Chief Executive Officer (CEO)
  • Appointment is effective immediately

OTTAWA, ONTARIO–(April 3, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced the appointment of Guy Chamberland, M.Sc., Ph.D., an accomplished drug developer, as interim Chief Executive Officer (CEO). This appointment is effective immediately.

Dr. Chamberland has been Chief Scientific Officer & Regulatory Affairs of Tetra since June 2016. He has over 23 years’ experience in the development of new drugs in the pharmaceutical industry (Canada and USA). He worked more than 10 years as an executive in various biopharmaceutical companies and was a member of the investment committee of a venture capital fund for 7 years.

Tetra’s former CEO, Bernard Fortier, left the corporation today thereby terminating his role as Chief Executive Officer and member of the Board of Directors.

“We are thankful for Bernard’s contributions to Tetra’s activities,” stated André Rancourt, Chairman of the Board. “Guy’s role as interim CEO will be a tremendous asset at this stage of Tetra’s growth. He will maintain his role and responsibility as Chief Scientific Officer while ensuring the growth and strategic operations of the corporation.”

Chamberland will serve as interim Chief Executive Officer while the Board of Directors conducts a search for a new Chief Executive Officer.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princeps product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(438) 899-7575

For investors information, please contact:
[email protected]
(438) 504-5784

#Marijuana stocks just got less risky, GMP Securities says $N.ca $NXTTF.ca $TBP.ca $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 12:41 PM on Monday, March 26th, 2018

  • Recent developments on the political and regulatory end are likely to add stability to the emerging market, says Martin Landry, analyst with GMP Securities
  • Canada is poised to be an global leader in the cannabis space
  • This past Thursday saw Canada’s Senate voting on its second reading of Bill C-45, the so-called Cannabis Act which would legalize the recreational use of marijuana
  • bill passed 44 to 29

March 25, 2018 By Jayson MacLean

Canada’s still-developing cannabis sector has seen its share of fortunes won and lost over the past year, with stock prices skyrocketing in a matter of weeks over December and January, only to pull back considerably in the time since.

But recent developments on the political and regulatory end are likely to add stability to the emerging market, says Martin Landry, analyst with GMP Securities, who says Canada is poised to be an global leader in the cannabis space.

This past Thursday saw Canada’s Senate voting on its second reading of Bill C-45, the so-called Cannabis Act which would legalize the recreational use of marijuana. Although the vote was predicted to be tight, as some senators in favour of the legislation were out of Ottawa on committee work and Conservative senators promising to vote en masse against, the bill nevertheless passed 44 to 29.

That bodes well for the bill, says Landry, who projects a late summer/early fall opening up of the rec cannabis market.

“[The Senate vote] provides a positive read-through in our view for the potential outcome of the final third reading vote, as the majority of the Independent Senators Group appear to be aligned with the Liberals,” Landry said in a note to clients on Friday. “In a 3rd reading scenario where all Liberals and Conservatives vote for and against Bill C-45 respectively, this would suggest ~73 per cent of independents (versus 95 per cent at second reading) would need to vote in favour for Bill C-45 to become law.”

As well, this past week Health Canada released its fourth quarter 2017 data on medical marijuana use, finding that patient registrations were up 14 per cent on the quarter to 269,502, while total volume of medical cannabis grew around 10 percent on the quarter and around 34 per cent year-over-year, the best growth rate over the past three quarters, says Landry.

Also coming from Health Canada were summary results from public consultations on the new cannabis regulations, held during a 60-day period starting this past November. The consultations drew in approximately 4,000 responses, covering all aspects of the proposed regulations including licensing and permits, security clearance and cannabis tracking, product packaging and labelling and the medical use of cannabis.

Some notable results include strong support from respondents for a quick roll-out on regulations regarding cannabis edibles along with majority support for the government’s plans concerning licensing and product labelling and plain packaging.

Landry says that going forward the report should feed into guidance and regulations for industry participants. On the issue of product labelling, the analyst says that Health Canada’s push for plain packaging could make it “difficult for licensed producers to differentiate their brands on the basis of packaging, however advertising rules are not expected to be more restrictive than those for tobacco,” Landry says.

In all, Landry sees the ramped up medical market and the maturing regulatory landscape to be a win for Canadian companies, who now have a head start over the competition when it comes to the industrial production of cannabis within a tightly regulated environment.

Landry says that having LPs required to deliver secure and stable production has “led Canadian licensed producers to build pharmaceutical grade production facilities, develop solid cultivation know-how and create a large bank of genetics,” he says. “Combined with well capitalized balance sheets, we believe that Canadian LPs are well positioned to become global leaders in the cannabis sector.”

Source: https://www.cantechletter.com/2018/03/marijuana-stocks-just-got-less-risky-gmp-securities-says/

Tetra Bio-Pharma $TBP.ca Added to Leading #Cannabis ETF: Horizons Marijuana Life Sciences Index $HMMJ.ca

Posted by AGORACOM-JC at 8:23 AM on Tuesday, March 20th, 2018

Logo tetrabiopharma rgb web

  • Announced that it has been added to the Horizons Marijuana Life Sciences Index (HMMJ) managed by Horizons ETFs Management (Canada) Inc.
  • HMMJ was the first and is the world’s largest ETF offering direct exposure to North American-listed securities that are involved with marijuana bioengineering and production

OTTAWA, ONTARIO–(March 20, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has been added to the Horizons Marijuana Life Sciences Index (HMMJ) managed by Horizons ETFs Management (Canada) Inc.

HMMJ was the first and is the world’s largest ETF offering direct exposure to North American-listed securities that are involved with marijuana bioengineering and production. The HMMJ portfolio recently expanded to include ten new constituents, including Tetra.

“This is a very positive sign for our shareholders,” says Bernard Fortier, CEO of Tetra. “Having Horizons trusting us after completing a $11.5 million bought deal and in the process of a $ 4.5 million private placement is a strong message of confidence. Our clinical approach and pipe-line of products are unique and being added to this index reinforces the credibility of our approach to the financial community.”

HMMJ is an index (or passively managed) ETF, which seeks to replicate, to the extent possible, the performance of the North American Marijuana Index (the “Index”), net of expenses. The Index is designed to provide exposure to the performance of a basket of North American publicly listed life sciences companies with significant business activities in the marijuana industry. The Index selects from a current universe of companies that have operations that may include one or more of biopharmaceuticals, medical manufacturing, distribution, bio-products and other ancillary businesses related to the marijuana industry.

More info on: https://www.horizonsetfs.com/news/Press-Release/Horizons-ETFs-Completes-Rebalance-of-its-Marijuana

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princeps product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(438) 899-7575

For investors information, please contact:
[email protected]
(438) 504-5784

Tetra Bio-Pharma $TBP.ca Completes Acquisition of Remaining 20% Interest in PhytoPain Pharma Inc. $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:13 AM on Monday, March 19th, 2018

Logo tetrabiopharma rgb web

  • Announced the completion of the previously announced acquisition of the remaining 20% interest in its PhytoPain Pharma Inc. subsidiary
  • Transaction is an important milestone for Tetra Bio-Pharma and all our stakeholders

OTTAWA, ONTARIO–(March 19, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced the completion of the previously announced acquisition of the remaining 20% interest in its PhytoPain Pharma Inc. subsidiary (the “Transaction“) from entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation (collectively, the “Sellers“).

“The Transaction is an important milestone for Tetra Bio-Pharma and all our stakeholders,” said Bernard Fortier, Tetra’s CEO. “It allows Tetra to gain 100% control of PhytoPain Pharma, a key asset in the development of our pipeline of cannabinoid-based drugs and gives Tetra full flexibility to enter into other partnerships or agreements in the future.”

The purchase price for the Transaction was comprised of a combination of cash, promissory notes and common shares of Tetra, some of which will be released to the Sellers upon the achievement of key milestones. The terms of the Transaction are detailed in the Corporation’s news release dated January 2, 2018 which is available on SEDAR under the Corporation’s profile. The Corporation used $500,000 out of the proceeds from the recently completed bought deal offering to repay a portion of the principal amount owing to the Sellers under the promissory notes.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princeps product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(438) 899-7575

For investors information, please contact:
[email protected]
(438) 504-5784